A B S T R A C T We have examined the effects of' cholinergic blockade with 0.5 mg methscopolamine bromide, intramuscularly, on sleep-related and insulininduced growth hormone (GH) secretion. 17 normal young men were studied; 8 had sleep studies, and 12 (including 3 who also had sleep studies) had insulin tolerance tests (ITT) with 0.1 U/kg of regular insulin. After an adjustment night in the sleep laboratory, saline control night and methscopolamine night studies were done in random se(luence; study procedures in-(cluded electroencephalographic, electromyographic, and electrooculographic recordings, and blood sampling every 20 min for hormone radioimmunoassays. Prolactin levels were also measured during sleep. For methscopolamine night studies, the mean overall control GH level of 2.89+0.44 ng/ml and the mean peak control GH level of' 11.09±3.11 ng/ml were dramatically reduced to 0.75±0.01 and 1.04+0.25 ng/ ml, respectively (P < 0.0001 and <0.001). Despite virtual absence of' GH secretion during the night in every study subject, no meas.ured sleep characteristic was affected by methscopolamine, including total slow-wave sleep ( methscopolamine had only a marginial effect oIn the GH response to insulin hypoglycemiiia. None of nine time points diff'ered significantly, as was also the case with peak levels, mean inerements, and areas under the curves (P > 0.2). Analysis of' variance did, however, indicate that the lower GH concentrations achieved during ITT after methscopolamine (average 31.7% below control) were significantly different than control concentrations. We conclude that the burst of' GH secretion which normally occurs after sleep onset is primed by a cholinergic mechanism which does not influence slow-wave sleep. Cholinergic mechanisms do not appear to play an important role in sleeprelated prolactin secretion. The contrast between the complete suppression of sleep-related GH release and the relatively small inhibitory effect on ITTinduced GH secretion suggests that the neurotransmitter mechanisms, and presumably the pathways, which subserve sleep-related GH secretion in man may be different from those which mediate the GH response to pharmacologic stimuli such as insulin.
A B S T R A C T We have examined the effects of' cholinergic blockade with 0.5 mg methscopolamine bromide, intramuscularly, on sleep-related and insulininduced growth hormone (GH) secretion. 17 normal young men were studied; 8 had sleep studies, and 12 (including 3 who also had sleep studies) had insulin tolerance tests (ITT) with 0.1 U/kg of regular insulin. After an adjustment night in the sleep laboratory, saline control night and methscopolamine night studies were done in random se(luence; study procedures in-(cluded electroencephalographic, electromyographic, and electrooculographic recordings, and blood sampling every 20 min for hormone radioimmunoassays. Prolactin levels were also measured during sleep. For methscopolamine night studies, the mean overall control GH level of 2.89+0.44 ng/ml and the mean peak control GH level of' 11.09±3.11 ng/ml were dramatically reduced to 0.75±0.01 and 1.04+0.25 ng/ ml, respectively (P < 0.0001 and <0.001). Despite virtual absence of' GH secretion during the night in every study subject, no meas.ured sleep characteristic was affected by methscopolamine, including total slow-wave sleep (12.1 ±42.6% control vs. 10.3 ±2.5% drug, P > 0.2). Sleep prolactin levels were not changed by methscopolamine. In contrast to the abolition of sleep-related GH secretion, administration of
INTRODUCTION
The secretory patternis of growth hormone (GH)' and of' prolactin (PRL) are related to normal sleep. GH secretion is enhanced during the 90-120 min immediately following sleep onset in temporal association with periods of slow-wave sleep (1) (2) (3) . As much as 'Abbreviatiotns used in this paper: ANOVA, analysis of vari- ance; GH, growth hormone; ITT, insulin tolerance test; PRL, prolactin; REM, rapid-eye-movement.
70-90% of the total 24-h prodtuction of GH in aduilts may occulr during these 2 h. Elevated PRL levels during sleep do not occutr in a well-defined major secretory episode as is the case for GH; rather, substantial episodic irregtularity prevails throughout the night, with highest levels occurriing dturing the latter half of sleep (4, 5) . It has been reported (6), but not confirmed (7) , that nocturnal elevations in PRL levels are temporally related to the termination of periods of rapid-eye-movemenit (REM) sleep. For both hormones, a number of control experiments have indicated that the enhanced nocturnal hormone secretion is sleep-entrained, and not related to an intrinsic circadian rhythm or due to other sleep-associated parameters. These controls have included sleep deprivation, and studies of interrupted or shifted sleep (1, 4, 5, 8) .
A number of attempts have been made to modify sleep-related GH secretion. No detectable effect occurred with diphenylhydantoin, pentobarbital (1), chlorpromazine (1), hyperglycemia (9-12), phentolamine (11), or propranolol (11) . However, a variety of' fractors has been found to be capable of suppressing sleeprelated GH release, some without observable effect on slow-wave sleep (1, (13) (14) (15) (16) (17) (18) (19) (20) (21) . These include: imipramine (1), medroxyprogesterone acetate (13), clomiphene (14) , cyproheptadine (15) , somatostatin (16) , f'ree fatty acids (17) , relative obesity (18, 19) , advanced age with acromegaly (20) , the dwarfism associated with emotional deprivation (21) , and chronic alcoholism (22) . In most of' these instances, no effect on slow-wave sleep was noted, and in one study, the amount of' slow-wave sleep increased on nights when sleep-related GH secretion decreased (15) . Further, inhibition of' slow-wave' sleep with flurazepam was not accompanied by any change in sleep-related GH secretion (23) . Thus, the association of enhanced GH secretion at sleep onset with slowwave sleep appears neither causative nor obligate. The same conclusion was reached by Martin in a recent review (24) .
Identification of' factors capable of' influencing central neurotransmission which can also modulate sleeprelated GH secretion may help to establish the neural pathways and mechanisms which subserve physiologic GH release. Among the approaches to the study of neuropharmacologic modification is the use of receptor blocking agents. In previous work, we have demonstrated the moderate stimulatory effect on sleeprelated GH secretion of' the serotonin receptorblocking drug, methysergide (7). Sleep-related PRL secretion was profoundly suppressed by methysergide.
In an ongoing study of the eff'ects of neurotransmittermodulating agents on sleep-related pituitary hormone secretion, we report in this paper the effect of'cholinergic receptor blockade with methscopolamine bromide on sleep electroencephalogram (EEG) parameters, and serum GH and PRL levels. Because of' our previous demonstration of antipodal effects of' methysergide on sleep-related and insulin-provoked GH release (7) , and therefore the probability that different stimuli to GH release involve different neuropharmacologic pathways, we have also assessed the effect of' this agent on insuilin-induiced GH secretion.
METHODS
Subjects for the stuidy on sleep-related secretion were eight normal paid volunteers between the ages of' 19-30 yr. Insulinprovocative testing was also performed on 12 similar subjects, including 3 who had participated in the sleep study. The height/weight ratio of'all subjects was 2.36+0.08 cm/kg (19) .
All subjects had the f'ollowing normal studies: medical history, physical examination, complete blood count, blood chemistry profile and chest X ray. Written informed consent was obtained after a detailed verbal and written explanation of'the study.
Both the sleep and insulin studies were performed with a double-blind crossover design; the drug and placebo were administered in random se(quence. For the sleep study, an acclimatization night without blood sampling preceded the two study nights; subjects reported to the laboratory at 8:00 p.m., at which time a catheter was inserted into a forearm vein. At 10:00 p.m., either 0.5 mg methscopolamine bromide or 0.5 cm3 normal saline was administered intramuscularly, and at 10:30 p.m., the subject went to bed. A unipolar EEG, horizontal electrooculogram, and electromyogram were recorded f'rom 10:30 p.m. until 7:30 a.m. Recordings were performed on a model 7 polygraph (Grass Instrument Co., Q(uincy, Mass.) with a paper speed of 10 mm/s, calibrated for 50 ,u'V to produce a 7.5-mm deflection. Recordings were read blindly by a single investigator using sleep-stage criteria of' Rechtschaf'f'en and Kales (25) . During the night, 5-cm3 samples of'blood were taken every 20 min from the venous catheter, f'or hormone analysis. The catheter was kept open by slow infusion of 0.45% saline containing 3,000 U of heparin/liter. The total amount inf'used was up to 500 ml of' this solution.
For the insulin tolerance tests, f;asting subjects reported to the laboratory at 8:00 a.m., at which time a scalp vein needle was inserted into a forearm vein, and a slow inf'usion of 0.45% saline was started. At 8:30 a.m. the subjects received 0.5 mg methscopolamine or 0.5 cln3 saline intramuscularly, and at 9:00 a.m., 0.1 U/kg of' regular insulin was administered intravenously. 5-cm3 blood samples were drawn for glucose and hormone measurement every 15 min for 2 h. All specimens for GH and PRL assay were allowed to clot, the serum was promptly separated and stored at -180C.
Determinations of' GH and PRL were performed by radioimmunoassay (26, 27) . The antisera, standards and tracer, and current details of' the GH method have been recently described (28) . The usual sensitivities of' the assays were 0.5 ng/ml of' serum for GH and 1.5 ng/ml for PRL. Blood glucose determinations were done using a glucose oxidase techni(que. Hormonal data during sleep were processed by an analysis of' variance (ANOVA) derived f'rom the Statistical Analysis System computer package (29) . For the purposes of'this analysis, the data were divided into three time periods, hours 1 and 2, hours 3 and 4, and hours 5-8 after the start of' sleep. The data were subjected to a logarithmic10 transf'ormation for normalization (30) , and partial sums of' squares were employed because of the unbalanced, nonorthogonal design. This analysis allowed separate examination of the contributions of the total variance of differences between subjects, the effects of time period, sleep stages, and drug treatment, and the interactions between treatment and time period and between treatment and sleep stage (Tables III and XI) . For the purpose of statistical analysis, all hormonal determinations which were undetectable were assigned a value equal to the detection limit in the particular assay in which they were included. All samples f'rom any one subject were included in the same assay.
As usual, the GH responses during ITT exhibited great variability among subjects; a wide range ofvalues was observed for the magnitude, time of onset of rise, and time ofpeak increment. Therefore, these data were analyzed in a variety of' ways, both before and after log10 transf'ormation for each method of analysis. Mean GH levels at each time point were compared by paired and nonpaired t test. Peak GH levels, maximum GH increments over base line, and areas under the GH curves were subjected to paired t test. In addition, these data comparisons were also evaluated by a two-way ANOVA in the determination of a possible drug eff'ect (7). A table was constructed by subtracting the GH value at each time during the drug ITT from the corresponding GH value f'or the same time and from the same subject during the placebo ITT. In this table of differences, the 12 columiins represented the 12 subjects and the 9 rows represented the sampling times during ITT (0,15,30,45,60,75,90,105, and 120 min). In addition, to avoiding the problem of nonindependence of' multiple time points, this approach also permits the determination of'whether or not the two GH curves (Fig. 2 ) deviate f'rom parallelism with each other. Such a deviation is indicated if'the effect of'time is significant in the ANOXIA, since the difference between the two curves is the data base. The effect of drug treatment is determined by posing the question whether or not the overall mean of these data is significantly diff'erent f'rom zero. If not, the treatment is indicated not to have aff'ected the GH response to ITT. For the purposes of statistical analyses, all values of GH and PRL which were below the limit of detectability were recorded as being e(qual to that value. The results of all statistical analyses wvere similar whether original data or log,0 transformed data were used.
RESULTS
Sleep. Analysis of the sleep parameters is presented in Table I . Methscopolamine did not aff'ect the total sleep time, percentage of any individual sleep stage, or any other measured sleep paramiieter. In view of' the interest in the relation of GH secretion to slow-wave sleep, it should be noted that total slow-wave sleep (stages 3 and 4 coombined) was also unchanged.
Growth hormone. Sleep-related GH levels are shown in Fig. 1 . The mean+SE GH values for each sleep stage and time period on placebo and methscopolamine nights are given in Table II , and the results of the ANOVA f'or GH levels are presented in Table III . It is evident that administration of methscopolamine was associated with prof'ound suppression of'GH secretion. The overall mean GH level of 2.89±0.44 ng/ml and the mean peak of 11.09 +3.11 ng/ml during the placebo night were reduced by methscopolamine to 0.75+0.01 and 1.04+0.25 ng/ml, respectively (P < 0.0001 and < 0.001). In fact, <3% of' samples obtained oIn the methscopolamine nights contained detectable GH levels, and the highest value recorded on all drug nights was 2.6 ng/ml. This virtual absence of' GH secretion after the administration of' methscopolamine contrasts with the normial GH pattern on placebo nights, the highest values occurring in a well-defined secretory episode during the first 2 h of' sleep. ANOVA revealed both time period alone and time-drug treatment interaction to be highly significant variables, reflecting the normal occurrence of'hormone secretion in early sleep (P < 0.0001 for both parameters, (1) (6b) (1) (:3) 
(1)
(1) Fig. 2 . The magnittude andcl dutrationi of the hypoglycemia were virtutally idenitical in both circtumiistanices. The GH response duirinig the control inisuilini toleranee Table IV , and the results of'the ANOVA are found in Table V . As in the case of' GH, there were great differences between individtuals. Neither sleep I at 75 min; the stages, methscopolamine treatment, nor interaction ef:
and the mean f'ects had a significant influence on nocturnal PRL levels.
were also not The concentrations of'PRL were in f;act niearly identical values (P > 0.2 through most of the observation period (Fig. 3) . Howthe GH curves ever, PRL levels were significantly related to the time ever, the rise in of' night, with values increasinig toward morning earlier than that (P < 0.0001, Table XI ). 
(1) The effect of methscopolamine on insulin-induced GH secretion was not significant by any of the methods of statistical assessment employed save one, the ANOVA. This was true whether the raw data or the log10 transformed data were used. The difference in the magnitude of methscopolamine action in the two GH secretory situations is so great that a qualitative difference in the mechanisms of action must be one of the possibilities entertained to explain the discrepancy. We have previously reported an even more marked dissociation of pharmacologic effects on sleep-related and insulin-induced GH secretion (7) . In that case, methysergide, a serotonin receptor blocker, was found to produce increased sleep-related, but decreased insulin-induced secretion. Thus, there is precedent for We presume that the profound suppression of sleeprelated GH levels observed in this study after administration of methscopolamine bromide is related to the anticholinergic properties of this agent. The dose employed was relatively small, and the pharmacologic specificity of action of the belladonna alkaloids is quite good as long as very large doses are not used (31) . Inasmuch as quaternary ammonium derivatives like methscopolamine bromide do not readily cross the bloodbrain barrier (31) (32) (33) (34) (35) , the site of drug action in the studies reported here may well be in the median eminence or its immediate environs, one of the few areas in the central nervous system with an incomplete blood-brain barrier, or possibly in the pituitary itself. However, such putative sites of action cannot be in a main final common neural pathway, since the drug was relatively impotent in blocking the GH response to insulin hypoglycemia.
There are few data bearing on the possible role of the cholinergic system in GH regulation in man. Salvadorini et al. (36) have described increased daytime GH secretion in response to intravenous administration of cytidine diphosphate choline. These data, as well as those we have obtained, suggest that the cholinergic system plays a facilitatory role in GH secretion, assuming bioavailability of choline from this agent to serve as an acetylcholine precursor. If further data continue to support the interpretation that cholinergic influences may stimulate GH secretion, than an explanation for previous apparently discrepant findings may emerge. We have reported increased GH levels during sleep after methysergide, a serotonin blocker of high pharmacologic specificity (7). In contrast, Chihara et al. (15) have reported suppression of GH levels during sleep after cyproheptadine, a drug which has serotonin-, histamine-, acetylcholine-, and dopamine-blocking properties (37, 38) . Cyproheptadine is in fact a rather potent anticholinergic, and its ability to suppress GH levels during sleep may be related to its anticholinergic properties. In this regard, it also seems plausible that the suppressive effects of imipramine on sleep-related GH secretion observed by Takahashi et al. a decade ago (1) were caused by the substantial anticholinergic effects of this drug rather than by its effects on amine re-uptake. There is no available information at present on the effects of anticholinergic drugs on daytime GH responses to secretagogues other than insulin.
Despite profound suppression of sleep-related GH secretion, methscopolamine had no effect on sleep in the present study (Table I) . Failure of this drug to affect sleep has been previously reported (39) , and is presumably due, at least in part, to its poor penetrance of the blood-brain barrier (31) (32) (33) (34) (35) . These considerations suggest, as noted above, that the effects of methscopolamine on sleep-related GH secretion are probably exerted at the level of the hypothalamus or the pituitary. Failure to block the GH response to insulin hypoglycemia makes it less likely, but not impossible, that the somatotrope cell is directly responsive to the drug. Although we do not know where methscopolamine is acting to achieve the differential effects reported here on sleep-related and insulin-induced GH secretion, we hypothesize, based on knowledge of the drug's inability to cross the blood-brain barrier, that this action takes place within the mediobasal hypothalamus. A neuronal locus within this general area which is functionally proximal to the final common pathway for GH secretion is suggested. Thus, we would speculate, based on the present results, that one or more pools of cholinergic neurons may abut on portions of the ventromedial or arcuate nuclei, or perhaps on neural elements of the infundibulum, which participate critically in the final common pathway for the regulation of GH secretion in man. Methscopolamine is thus added to a growing list of factors capable of dissociating sleep-related GH secretion and slow-wave sleep (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) . We conclude that these two phenomena have no necessary neurophysiologic linkage.
Our data demonstrate no effect of methscopolamine on sleep-related PRL secretion. Though an inhibitory cholinergic influence on serum PRL levels in rats has been suggested (40) (41) (42) (43) , there are no comparable published data in humans. The data presented in this study suggest that the cholinergic system does not play an important role in the regulation of sleep-related PRL secretion in man.
